CNS Drugs

, Volume 22, Issue 7, pp 613–617 | Cite as

Spotlight on Bupropion in Major Depressive Disorder

  • Sohita Dhillon
  • Lily P. H. Yang
  • Monique P. Curran
Adis Spotlight


Bupropion is presumed to be a dopamine-noradrenaline (norepinephrine) reuptake inhibitor and is an effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin®] administered three times daily; (ii) bupropion sustained release (SR) [Wellbutrin SR®] administered twice daily; and (iii) bupropion extended/modified release (XR) [Wellbutrin XL®/Wellbutrin XR®] administered once daily. All three formulations are bioequivalent in terms of systemic exposure to bupropion.

Oral three-times-daily bupropion IR was effective and generally well tolerated in the treatment of major depressive disorder (MDD). It was as efficacious and as well tolerated as some TCAs and the SSRI fluoxetine. Moreover, it was associated with less somnolence and weight gain than some TCAs. Twice-daily bupropion SR was also efficacious and generally well tolerated in the treatment of MDD. It was as effective as and had a generally similar tolerability profile to some SSRIs, but had the advantage of less somnolence and sexual dysfunction. The efficacy of bupropion XR in terms of primary efficacy measures was established in two of six well designed placebo-controlled studies. Bupropion XR also demonstrated efficacy in terms of some secondary outcomes in five of these studies. Additionally, bupropion XR was similar, in terms of the primary efficacy outcomes, to the SSRI escitalopram in two placebo-controlled trials and to the serotonin-noradrenaline reuptake inhibitor (SNRI) venlafaxine extended release (XR) in two trials (one of which was placebo-controlled), but not in a third placebo-controlled trial where venlafaxine XR was better than bupropion XR. It was generally as well tolerated as escitalopram and venlafaxine XR, but was associated with less sexual dysfunction than escitalopram. Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration.


Major Depressive Disorder Sustained Release Bupropion Major Depressive Disorder Escitalopram 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Dhillon S, Yang LPH, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68(5): 653–89PubMedCrossRefGoogle Scholar
  2. 2.
    GlaxoSmithKline. Wellbutrin (bupropion hydrochloride): US prescribing information [online]. Available from URL: [Accessed 2008 Jan 15]
  3. 3.
    GlaxoSmithKline. Wellbutrin SR (bupropion hydrochloride sustained-release tablets): US prescribing information [online]. Available from URL: [Accessed 2008 Jan 15]
  4. 4.
    GlaxoSmithKline. Wellbutrin XL (bupropion hydrochloride extended-release): US prescribing information [online]. Available from URL: [Accessed 2008 Jan 15]
  5. 5.
    Heads of Medicines Agencies. Wellbutrin XR: summary of product characteristics [online]. Available from URL: [Accessed 2008 Mar 4]
  6. 6.
    Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004 Sep; 66(3): 675–82PubMedCrossRefGoogle Scholar
  7. 7.
    Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7(3): 106–13PubMedCrossRefGoogle Scholar
  8. 8.
    GlaxoSmithKline. Steady-state bioequivalence evaluation of bupropion sustained-release and bupropion immediate-release tablets in healthy male volunteers (study no. 206) [online]. Available from URL: [Accessed 2008 Jan 15]
  9. 9.
    GlaxoSmithKline. A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCl 300mg extended release tablets (1 × 300mg q.d.) versus Wellbutrin 100mg tablets (t.i.d.) in normal healthy non-smoking male and female subjects (study no. AK1BI-OVAIL2543) [online]. Available from URL: [Accessed 2008 Jan 15]
  10. 10.
    Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005 Nov; 27(11): 1685–95PubMedCrossRefGoogle Scholar
  11. 11.
    Odishaw J, Chen C. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 2000 Dec; 20(12): 1448–53PubMedCrossRefGoogle Scholar
  12. 12.
    Hogeland GW, Swindells S, McNabb JC, et al. Lopinavir/ ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007 Jan; 81(1): 69–75PubMedCrossRefGoogle Scholar
  13. 13.
    Lineberry CG, Johnston JA, Raymond RN, et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990 May; 51(5): 194–9PubMedGoogle Scholar
  14. 14.
    Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991 Aug; 52(8): 329–35PubMedGoogle Scholar
  15. 15.
    Masco HL, Kiev A, Holloman LC, et al. Safety and efficacy of bupropion and nortriptyline in outpatients with depression. Curr Ther Res Clin Exp 1994; 55(7): 851–63CrossRefGoogle Scholar
  16. 16.
    Mendels J, Amin MM, Chouinard G, et al. A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 118–20PubMedGoogle Scholar
  17. 17.
    Feighner J, Hendrickson G, Miller L, et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986 Feb; 6(1): 27–32PubMedCrossRefGoogle Scholar
  18. 18.
    Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994 Jun; 14(3): 170–9PubMedCrossRefGoogle Scholar
  19. 19.
    Reimherr FW, Cunningham LA, Batey SR, et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther 1998 May–1998 30; 20: 505–16PubMedCrossRefGoogle Scholar
  20. 20.
    Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999 Dec; 11(4): 205–15PubMedGoogle Scholar
  21. 21.
    Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr; 21(4): 643–58PubMedCrossRefGoogle Scholar
  22. 22.
    Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001 Jul; 23(7): 1040–58PubMedCrossRefGoogle Scholar
  23. 23.
    Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002 May 1; 51(9): 753–61PubMedCrossRefGoogle Scholar
  24. 24.
    Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997 Dec; 58(12): 532–7PubMedCrossRefGoogle Scholar
  25. 25.
    Weihs KL, Settle Jr EC, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000 Mar; 61(3): 196–202PubMedCrossRefGoogle Scholar
  26. 26.
    Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 Mar 23; 354(12): 1231–42PubMedCrossRefGoogle Scholar
  27. 27.
    Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 Mar 23; 354(12): 1243–52PubMedCrossRefGoogle Scholar
  28. 28.
    Thase ME, Clayton AH, Chrzanowski W, et al. Bupropion extended release and venlafaxine extended release for the treatment of depression: results from three multicenter trials [abstractno. 146]. 14th Congress of Psychiatry of the Association of European Psychiatrists; 2006 Mar 4–8; NiceGoogle Scholar
  29. 29.
    Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006 Jun; 67(6): 865–73PubMedCrossRefGoogle Scholar
  30. 30.
    Hewett K, Chrzanowski W, Rousseau R, et al. Efficacy and safety of bupropion XL in elderly patients with major depressive disorder [abstract no. P.2.c.006 plus poster]. Eur Neuropsychopharmacol 2006; 16Suppl. 4: S315–16Google Scholar
  31. 31.
    Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006 May; 67(5): 736–46PubMedCrossRefGoogle Scholar
  32. 32.
    Thase ME, Clayton AH, Haight BR, et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006 Oct; 26(5): 482–8PubMedCrossRefGoogle Scholar
  33. 33.
    Croft HA, Wightman D, Hewett K, et al. Additional data on the safety and tolerability of bupropion extended-release: newly accumulated data extends previous findings in placebo controlled clinical trials [abstract no. NR484 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–25; Toronto (ON)Google Scholar
  34. 34.
    Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999 Mar; 21(3): 454–63PubMedCrossRefGoogle Scholar
  35. 35.
    Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991 Nov; 52(11): 450–6PubMedGoogle Scholar
  36. 36.
    Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005 Aug; 66(8): 974–81PubMedCrossRefGoogle Scholar
  37. 37.
    Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 2001 Dec; 35(12): 1608–13PubMedCrossRefGoogle Scholar
  38. 38.
    Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000 Apr; 20(2): 122–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Sohita Dhillon
    • 1
    • 2
  • Lily P. H. Yang
    • 1
    • 2
  • Monique P. Curran
    • 1
    • 2
  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations